Saturday, June 4, 2022, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Prostate Cancer

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Andrew J Armstrong, MD, ScM
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

Alan H Bryce, MD
Chair, Division of Hematology and Medical Oncology
Chair, Genitourinary Disease Group
Mayo Clinic
Phoenix, Arizona


Alicia K Morgans, MD, MPH
Genitourinary Medical Oncologist
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, and Sanofi Genzyme.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

MODULE 1: Optimal Application of Hormonal Therapy in Prostate Cancer Management

  • Major efficacy and safety findings with the oral GnRH antagonist relugolix in men with advanced prostate cancer; patient selection for and optimal integration of relugolix
  • Recently presented findings from the STAMPEDE platform assessing the addition of abiraterone and prednisolone with or without enzalutamide to androgen deprivation therapy for high-risk nonmetastatic prostate cancer
  • Ongoing and planned Phase III trials investigating secondary hormonal agents for nonmetastatic hormone-sensitive prostate cancer (HSPC)
  • Clinical, biologic and practical factors in the selection of enzalutamide, apalutamide or darolutamide for patients with nonmetastatic castration-resistant prostate cancer (CRPC)
  • Long-term follow-up from Phase III studies supporting the use of abiraterone, enzalutamide or apalutamide for metastatic HSPC (mHSPC); considerations influencing treatment selection
  • Published efficacy and safety data from the Phase III ARASENS trial of darolutamide in combination with docetaxel and ADT in mHSPC; implications for clinical practice
  • Key efficacy and safety results from the Phase III PEACE-1 study of androgen deprivation therapy and docetaxel with or without abiraterone with or without local radiation therapy for mHSPC

MODULE 2: Selection and Sequencing of Therapy for Patients with Metastatic CRPC (mCRPC); Novel Investigational Strategies

  • Major efficacy and safety findings informing the optimal sequencing of cabazitaxel for patients with mCRPC, including those with poor-prognosis disease
  • Patient selection for radium-223 and optimal integration into treatment algorithms
  • Effect of the addition of bone-protecting agents to radium-223/enzalutamide therapy in the Phase III EORTC-1333/PEACE III trial and implications for practice
  • Clinical relevance of PSMA expression in prostate cancer and mechanism of action of the novel radioligand 177Lu-PSMA-617
  • Design, eligibility criteria and key efficacy and safety findings from the pivotal Phase III VISION study leading to the recent approval of 177Lu-PSMA-617 for patients with progressive PSMA-positive mCRPC; optimal integration into clinical practice
  • Findings from the mCRPC cohort of the Phase Ib COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab; ongoing Phase III CONTACT-02 trial
  • Other novel agents and strategies under investigation for mCRPC

MODULE 3: Current and Future Role of PARP Inhibitors in the Management of Prostate Cancer

  • Frequency of homologous recombination repair (HRR) gene mutations in prostate cancer; indications for and practical implementation of genetic testing
  • Long-term efficacy and safety findings with olaparib or rucaparib monotherapy for patients with mCRPC
  • FDA-approved indications for olaparib and rucaparib for mCRPC and optimal integration into management algorithms
  • Biologic basis for combining PARP inhibitors with androgen receptor-targeted therapies in prostate cancer
  • Recently presented efficacy and safety findings from the Phase III PROpel trial evaluating olaparib and abiraterone versus abiraterone alone as first-line therapy for patients with mCRPC with or without HR gene mutations
  • Available data from the Phase III MAGNITUDE study of niraparib with abiraterone and prednisone as first-line therapy for patients with mCRPC with or without HRR gene alterations
  • Other ongoing Phase III studies evaluating the role of PARP inhibitors combined with secondary hormonal agents for mCRPC (eg, CASPAR, TALAPRO-2) and mHSPC (eg, TALAPRO-3, AMPLITUDE)

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise published research findings and current guideline recommendations on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and counsel patients about the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options for patients.
  • Explore available data with treatment intensification using cytotoxic and/or secondary hormonal therapy for metastatic hormone-sensitive prostate cancer, and effectively integrate these approaches into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available options for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess available research supporting the use of PARP inhibitors alone or with secondary hormonal therapies for patients with mCRPC, and discern how to optimally incorporate these agents into current and future treatment plans.
  • Appreciate available Phase III data leading to the recent FDA approval of PSMA-targeted radioligand therapy for progressive PSMA-positive mCRPC, and consider the optimal integration of this strategy into clinical care.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Bryce has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr ArmstrongAdvisory Committee: Advanced Accelerator Applications, Exelixis Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc; Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, FORMA Therapeutics, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc; Contracted Research (to Institution): Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, FORMA Therapeutics, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc. Dr MorgansAdvisory Committee: Bayer HealthCare Pharmaceuticals, Gilead Sciences Inc, MyovantSciences; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, Lantheus, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme, Telix Pharmaceuticals; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Myovant Sciences, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, and Sanofi Genzyme.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of prostate cancer.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.